1. Home
  2. ATRC vs COLL Comparison

ATRC vs COLL Comparison

Compare ATRC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATRC
  • COLL
  • Stock Information
  • Founded
  • ATRC 2000
  • COLL 2002
  • Country
  • ATRC United States
  • COLL United States
  • Employees
  • ATRC N/A
  • COLL N/A
  • Industry
  • ATRC Medical/Dental Instruments
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATRC Health Care
  • COLL Health Care
  • Exchange
  • ATRC Nasdaq
  • COLL Nasdaq
  • Market Cap
  • ATRC 1.1B
  • COLL 1.0B
  • IPO Year
  • ATRC 2005
  • COLL 2015
  • Fundamental
  • Price
  • ATRC $39.84
  • COLL $30.72
  • Analyst Decision
  • ATRC Strong Buy
  • COLL Strong Buy
  • Analyst Count
  • ATRC 9
  • COLL 5
  • Target Price
  • ATRC $43.00
  • COLL $43.60
  • AVG Volume (30 Days)
  • ATRC 618.4K
  • COLL 441.9K
  • Earning Date
  • ATRC 02-12-2025
  • COLL 02-20-2025
  • Dividend Yield
  • ATRC N/A
  • COLL N/A
  • EPS Growth
  • ATRC N/A
  • COLL 757.11
  • EPS
  • ATRC N/A
  • COLL 2.16
  • Revenue
  • ATRC $447,573,000.00
  • COLL $599,245,000.00
  • Revenue This Year
  • ATRC $18.02
  • COLL $13.25
  • Revenue Next Year
  • ATRC $12.93
  • COLL $18.14
  • P/E Ratio
  • ATRC N/A
  • COLL $14.24
  • Revenue Growth
  • ATRC 17.56
  • COLL 9.62
  • 52 Week Low
  • ATRC $18.94
  • COLL $28.39
  • 52 Week High
  • ATRC $43.11
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • ATRC 61.66
  • COLL 45.90
  • Support Level
  • ATRC $39.71
  • COLL $32.28
  • Resistance Level
  • ATRC $43.11
  • COLL $33.45
  • Average True Range (ATR)
  • ATRC 1.86
  • COLL 1.07
  • MACD
  • ATRC 0.15
  • COLL -0.16
  • Stochastic Oscillator
  • ATRC 63.10
  • COLL 2.05

About ATRC AtriCure Inc.

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: